Tumor response after [90Y-DOTA0,Tyr3]-octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size

Journal of Nuclear Medicine

Volumn 42, Issue 12, 2001, Pages 1841-1846

  De Jong, M ^a   Breeman, W A P ^a   Bernard, B F ^a   Bakker, W H ^a   Visser, T J ^a   Kooij, P P M ^a   Van Gameren, A ^a   Krenning, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

90Y DOTA0,Tyr3 octreotide; Curability; Peptide receptor radionuclide therapy; Rat; Tumor size

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; [1,4,7,10 TETRAAZACYCLODECANE N,N',N'',N''' TETRAACETIC ACID TYROSINE 3]OCTREOTIDE Y 90; OCTREOTIDE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; YTTRIUM 90;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SIZE; CLONOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; HYPOXIA; ISOTOPE LABELING; MALE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION ENERGY; RAT; TREATMENT OUTCOME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; MALE; NEOPLASM TRANSPLANTATION; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; YTTRIUM RADIOISOTOPES;

EID: 0035665806     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Somatostatin and its receptor family
2. The somatostatin receptor family
3. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors
4. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
5. 3]-octreotide: The Rotterdam experience with more than 1000 patients
6. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide
7. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
8. 111In-pentetreotide: Initial observations and future directions
9. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome
10. 111Inpentetreotide: State of the art and perspectives
11. Antiproliferative effect of radiolabelled octreotide in a metastases model in rat liver
12. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues
13. Somatostatin analogues for somatostatinreceptor-mediated radiotherapy of cancer
14. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
15. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model
16. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats
17. Re-RC-160, a directly-radiolabeled somatostatin analogue
18. 3]octreotide, a promising somatostatin analogue for radionuclide therapy
19. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
20. 111In-DTPA-octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake
21. 3-octreotide: Preliminary report in cancer patients
22. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy
23. Yttrium-90 DOTATOC: First clinical results
24. Yttrium-90-labelled somatostatin-analogue for cancer treatment
25. 90Y-SMT487 (OctreoTher): A phase 1 study
26. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy
27. Absorbed fractions for electrons and beta particles in spheres of various sizes
28. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
29. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy
30. Internalization of indium111 into human neuroendocrine tumor cells after incubation with indium-111DTPA-D-Phe1-octreotide
31. 111In-pentetreotide in rats
32. 3]octreotide is dependent on the peptide amount